CCO Management Series
Minimizing Barriers and Maximizing Response: Strategies and Tools for Frontline Providers Caring for Patients With Chronic Hepatitis C
Interactive Case Challenges
Management of a Patient With Hepatitis C Genotype 1 Infection Who Relapsed After a Course of Standard Interferon and Ribavirin
|
Program Director: Gregory T. Everson, MD, FACP
- Tiffany A. Geahigan, PA-C, CCRC
|
|
|
Join Tiffany A. Geahigan, PA-C, CCRC, in choosing the optimal treatment strategies for an obese black patient with hepatitis C genotype 1 who relapsed after a course of standard-dose interferon alfa and ribavirin.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss factors associated with response and nonresponse in hepatitis C
- Describe strategies for the management of HCV-infected patients with multiple negative predictors of response
- Describe the manifestations and management strategies for interferon-induced thyroid abnormalities
|
Retreatment in a Patient Failing Previous Therapy
|
|
|
Anne Croghan, MN, ARNP, discusses treatment options and predictors of response for patients relapsing on previous peginterferon/ribavirin therapy.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize factors associated with favorable and unfavorable responses to peginterferon/ribavirin in patients with chronic hepatitis C
- Discuss the role of maintenance therapy in patients with chronic hepatitis C
- Recount the advantages and disadvantages of high-dose induction therapy and extension therapy in patients with hepatitis C
|
Management of an HCV-Infected Male With Advanced Liver Disease
|
Program Director: Gregory T. Everson, MD, FACP
- Gregory T. Everson, MD, FACP
|
|
|
Gregory T. Everson, MD, FACP, discusses management strategies for a patient with advanced hepatitis C.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recount the treatment goals of hepatitis C virus (HCV)-infected patients with advanced liver disease
- Identify factors associated with decreased treatment response among HCV-infected patients with advanced liver disease
- Discuss treatment modifications for HCV-infected patients with advanced liver disease
- Describe the complications associated with advanced liver disease
|
Virtual Presentations
Hepatitis C: Maximizing Therapeutic Response
|
Program Director: Michael W. Fried, MD
|
|
Michael W. Fried, MD, discusses strategies to tailor HCV treatment according to a patient’s individual response.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recount key data regarding HCV treatment dosing and its relationship to treatment outcomes
- Describe the effects of discontinuing therapy on overall treatment responses
- Discuss strategies to tailor HCV treatment to individual patient responses
|
Slideset: Hepatitis C: Maximizing Therapeutic Response
 |
|
Michael W. Fried, MD, discusses strategies to tailor HCV treatment according to a patient’s individual response.
Format: Microsoft PowerPoint (.ppt) |
File size: 1.44 MB
| Date posted: 7/9/2008
|
Managing the Difficult-to-Treat HCV Patient
|
|
|
K. Rajender Reddy, MD, discusses considerations for the management of HCV-infected patients who are nonresponders or relapsers to previous HCV therapy.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the patterns and predictors of response to treatment among hepatitis C virus (HCV)–infected patients
- Discuss strategies for preventing nonresponse and relapse among HCV-infected patients
- Recount data concerning current and future retreatment options for patients with previous treatment failure
|
Slideset: Managing the Difficult-to-Treat HCV Patient
 |
|
Download a slideset focused strategies for managing patients with previous nonresponse or relapse during HCV therapy.
Format: Microsoft PowerPoint (.ppt) |
File size: 1.16 MB
| Date posted: 3/13/2009
|
Tailoring HCV Treatment to Patients With Advanced Liver Disease
|
Program Director: Michael W. Fried, MD
  
- Douglas M. Heuman, MD, FACP
- HoChong Gilles, RN, MS, FNP
- Lisa Pisney, RN, MSN, ANP-C
|
|
|
Join Douglas M. Heuman, MD, FACP, as he discusses the impact of advanced fibrosis and cirrhosis on treatment approaches for HCV infection.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss both the benefits of achieving sustained virologic response and the limitations of antiviral treatment in HCV patients with fibrosis and cirrhosis
- Evaluate current approaches to address cytopenias during HCV treatment in patients with advanced liver disease
- Describe data assessing the efficacy of a low accelerating dose regimen in the treatment of HCV patients with decompensated cirrhosis
- Identify risk factors associated with progressive HCV and recurrent cirrhosis following liver transplantation
|
Slideset: Tailoring HCV Treatment to Patients With Advanced Liver Disease
 |
|
Download a slideset on the impact of advanced fibrosis and cirrhosis on treatment approaches for HCV infection for self study or use in your own presentations.
Format: Microsoft PowerPoint (.ppt) |
File size: 1.48 MB
| Date posted: 9/18/2008
|
Interactive Tools
HCV Drug Dose and Response
an Interactive Decision Support Tool
|
|
Interested in understanding more about HCV treatment dosing strategies with peginterferon and ribavirin and the factors involved in determining the best strategy for your patient?
This tool enables you to select specific patient characteristics that have been associated with treatment response in controlled studies and then view a convenient graphical summary of the key data from those studies. You can also print the data and/or download slides. Practical calculators that can be used to understand HCV drug dosing and the impact on treatment response are also included.
Format: Adobe Flash (.swf)
| File size: 397 KB
|
Key Questions for Patients Facing HCV Retreatment
an Interactive Decision Support Tool
|
|
Trying to find the optimal management strategies for your hepatitis C patients facing retreatment?
In just minutes, this tool highlights the key factors associated with treatment nonresponse and enables you to evaluate your patient’s previous course of therapy to better understand why it was not successful. This information can be used when considering the optimal strategy for retreatment. You can also download a worksheet questionnaire to use as an interviewing tool when speaking with your patient about his/her previous treatment course.
Format: Adobe Flash (.swf)
| File size: 394 KB
|
HCV Management in the Setting of Advanced Liver Disease
an Interactive Decision Support Tool
|
|
This tool is designed to guide healthcare providers through the diagnosis and management of hepatitis C virus (HCV) infection in the setting of advanced liver disease. This is achieved by 1) providing expert guidance on evaluating and monitoring patients with HCV infection and advanced liver disease, 2) providing clinicians with the latest data regarding the risks and outcomes related to initiating HCV therapy according to management strategies and key patient and viral characteristics, and 3) highlighting eligibility for treatment or other management strategies such as liver transplantation.
Format: Adobe Flash (.swf)
| File size: 143 KB
|
Disclaimer:
The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|